1. New Directions in iTTP

3. Program Overview

4. Improving the iTTP Prognosis

5. Pathophysiology of iTTP

6. TTP May Be Associated With Other Conditions

7. Pathophysiology of iTTP (cont)

8. Treatment Strategies for TTP Based on Pathophysiologic Model

9. Diagnosing iTTP

10. Predicting ADAMTS13 Deficiency Based on Clinical and Standard Biological Features

11. Predicting ADAMTS13 Deficiency Based on Clinical and Standard Biological Features (cont)

12. Unmet Needs with Current Treatment

13. Managing Suboptimal Response to Therapy

14. New Therapies for iTTP: HERCULES Study

15. HERCULES Study: Key Results

16. HERCULES Study: Secondary Endpoints

17. HERCULES Study: Safety

18. Recombinant ADAMTS13 for cTTP

19. Recombinant ADAMTS13 for cTTP (cont)

20. Preventing Relapse After Therapy for iTTP

21. Preventing Relapse After Therapy for iTTP (cont)

22. Outlook With New Therapies

23. Changing the Treatment Paradigm

24. Changing the Treatment Paradigm (cont)

25. Monitoring Long-Term Complications

26. Abbreviations